Nicolas Chronos, MD
Cardiovascular Disease · Eatonton, GANPI 1427057165
Payments from drug & device makers
What this record shows
This record is dominated by other: $907,163 of the $912,352 with a category attached, or 99.4%. Edwards Lifesciences accounts for 99.5% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2024 at $890,542 and has fallen 98.0% since, to $18,167 in 2025. Among cardiovascular disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 222 payments — averaging $4109.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$907K
- Novartis$1K
- Novo Nordisk$458
- Abbott$372
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$334
- AstraZeneca$250
- plus $2K from 26 others
Across 670 payments — averaging $2186.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$669K
- Modernatx, Inc.$193K
- Akebia Therapeutics Inc$190K
- Johnson & Johnson$115K
- Regeneron$101K
- Alnylam Pharmaceuticals Inc.$52K
- plus $145K from 9 others
What the payments were for
- Speaking & faculty fees$7920%
- Food & beverage$4,3960%
- Other$907,16399%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 9 | $907,417 |
| Novartis | 16 | $1,093 |
| Novo Nordisk | 24 | $458 |
| Abbott | 14 | $372 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $334 |
| AstraZeneca | 16 | $250 |
| Johnson & Johnson | 15 | $217 |
| Cvrx, Inc. | 3 | $215 |
| Dexcom, Inc. | 10 | $210 |
| Amgen | 15 | $209 |
| E.r. Squibb & Sons, L.L.C. | 13 | $208 |
| Merck | 11 | $178 |
| Impulse Dynamics (USA) Inc. | 5 | $174 |
| Boehringer Ingelheim | 10 | $174 |
| Kowa Pharmaceuticals America, Inc. | 7 | $113 |
| Pfizer | 7 | $113 |
| Mylan Specialty L.p. | 7 | $110 |
| Amarin Pharma, Inc. | 6 | $93 |
| Biotronik Inc. | 1 | $71 |
| Lilly USA, LLC | 2 | $63 |
| Esperion Therapeutics, Inc. | 2 | $45 |
| Senseonics, Incorporated | 1 | $36 |
| Beckman Coulter, Inc. | 1 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$792
- Barostim Neo System$186
- MitraClip$170
- SAPIEN 3 Ultra RESILIA$150
How this compares
$912,352 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 761 | $919,192 |
| XareltoRivaroxaban | 207 | $270,103 |
| EntrestoSacubitril/Valsartan | 204 | $228,352 |
| Repatha SureclickEvolocumab | 259 | $203,901 |
| OzempicSemaglutide | 176 | $192,965 |
| FarxigaDapagliflozin Propanediol | 180 | $167,321 |
| MounjaroTirzepatide | 120 | $132,190 |
| JardianceEmpagliflozin | 82 | $101,759 |
| JanuviaSitagliptin Phosphate | 64 | $72,212 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $40,821 |
| MultaqDronedarone Hcl | 21 | $39,561 |
| RybelsusSemaglutide | 19 | $34,985 |
| BrilintaTicagrelor | 42 | $33,096 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $32,392 |
| TrulicityDulaglutide | 30 | $28,371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $113 | $925,602777 claims |
| Johnson & JohnsonXarelto | $217 | $270,103207 claims |
| NovartisEntresto | $1,093 | $228,352204 claims |
| Novo NordiskOzempic, Rybelsus | $458 | $227,949195 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $250 | $208,212245 claims |
| Lilly USA, LLCMounjaro, Trulicity | $63 | $160,561150 claims |
| Boehringer IngelheimJardiance, Tradjenta | $174 | $115,25794 claims |
| MerckJanuvia, Janumet, Belsomra | $178 | $88,97992 claims |
| AbbVieLinzess, Synthroid | $12 | $28,514152 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $113 | $25,08641 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Eatonton
- Narendra SinghJohns Creek$1.6M
- Hunter ChampionColumbus$1.5M
- Jaime BurkleGainesville$628K
- Joseph MillerAtlanta$573K
- Kashyap ChoksiThomasville$263K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
- Hiren ShahColumbus$166K
- Mani VannanAtlanta$157K
- Victor CorriganAtlanta$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.